November 14th Options Now Available For Moderna (MRNA)

The article details options strategies for Moderna (MRNA), currently trading at $27.30/share, offering investors pathways to acquire stock at a discount or enhance portfolio yield. Selling a $25 strike put for a $1.52 premium provides a potential acquisition cost basis of $23.48 (an 8% discount) with a 69% probability of expiring worthless, yielding a 51.56% annualized return on the cash commitment. Alternatively, a covered call strategy using a $29 strike call for a $2.11 premium on existing MRNA shares could generate a 13.96% return if called away by November 14th, or a 65.54% annualized premium if it expires worthless, leveraging current implied volatility around 79%.

Analysis

The options market for Moderna (MRNA), currently trading at $27.30, presents opportunities for yield enhancement and discounted stock acquisition, primarily driven by an elevated implied volatility of approximately 79%, which is significantly higher than its trailing twelve-month historical volatility of 66%. This volatility premium makes option-selling strategies particularly noteworthy. For investors seeking to acquire shares, selling the $25.00 strike put contract for a $1.52 premium creates an effective cost basis of $23.48, representing an 8% discount to the current price. Analytical models suggest a 69% probability of this put expiring worthless, which would translate to a 51.56% annualized return on the cash commitment. For existing shareholders, a covered call strategy at the $29.00 strike offers a potential total return of 13.96% by the November 14th expiration if the stock is called away. Should the call expire worthless, an event with a 52% calculated probability, the collected premium would provide a 65.54% annualized yield boost. These strategies allow investors to monetize the high current implied volatility without taking a view on the company's business fundamentals.

Key Decisions for Investors

• Investors bullish on MRNA but seeking a lower entry point could consider selling the $25.00 cash-secured put to either acquire the stock at an effective 8% discount or generate a 51.56% annualized yield if the stock price remains above the strike.
• Current MRNA shareholders could implement a covered call at the $29.00 strike to generate income, targeting a 13.96% total return if the stock is called away or collecting a premium equivalent to a 65.54% annualized yield boost if it is not.
• Given the notable spread between implied (79%) and historical (66%) volatility, investors should recognize that while selling options is currently attractive, it also caps upside potential and exposes sellers to assignment risk should the stock move sharply against their position.